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Prospective review of radiotherapy trials through implementation of standardised multi-
centre workflow and IT infrastructure 
Abstract  
Objectives  
We sought to develop a process that would allow us to perform prospective review of 
outlining in trials using expert reviewers based in multiple centres. 
Methods  
We implemented a specific IT infrastructure and workflow that could serve all organisations 
involved in the RTQA process 
Results 
Data was  processed and packaged in the Computational Environment for Radiotherapy 
Research binary format and securely transmitted to the expert reviewer at the designated 
remote organisation. It was opened and reviewed using the distributed CERR-compiled 
application and standardised report sent to the respective centre. Centres were expected to 
correct any unacceptable deviations and resubmit outlining for approval, prior to 
commencing treatment. 75% of reviews were completed and fed back to centres within 3 
working days.   There were no delays in treatment start date.  
Conclusion 
Our distributed RTQA review approach provides a method of prospective outlining review at 
multiple centres, without compromising quality, delaying start of treatment or need for 
significant additional resources.  Future progress in the area of prospective individual case 
review will need to be supported by additional resources for clinician time to undertake the 
reviews. 
Advances in knowledge 
Trial groups around the world have formulated different approaches to address the need for 
prospective review of radiotherapy data with clinical trials, in line with available resources. 
We report a UK solution that has allowed the workload for outlining review to be distributed 
across a wider group of volunteer reviewers, without the need for any additional 
infrastructure costs and has already been adopted within the UK radiotherapy trials 
community.  
Introduction 
It is now well established that radiotherapy (RT) trial outcomes are related to protocol 
compliance and quality of the delivered RT1-7. The detrimental effects of non-compliance to 
Manuscript
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protocol can be minimised by a robust RT Quality Assurance (RTQA) Programme3,8. UK RT 
trials are encouraged to undertake some form of pre-accrual assessment of outlining7 and 
planning, which can take the form of a benchmark case, or a dummy run9. While this 
approach is associated with improved protocol compliance3; to ensure the ongoing quality 
of the RT delivery within the trial, depending on the complexity of the RT, it should be 
complemented by some form of on-trial assessment (individual case review, ICR) 10.  
The UK National Radiotherapy Trials Quality Assurance (RTTQA) group operates from four 
sites, ours being one of the host sites.  Much of the ICR for trials supported by this group has 
been retrospective, in keeping with many other international trials. This does not allow 
protocol deviations to be identified and corrected prior to an individual patient commencing 
treatment. ARISTOTLE 1, a phase III trial for locally advanced rectal cancer, was the first trial 
in our RTTQA centre to undertake prospective ICR (prior to start of treatment), but was 
reliant on a single clinician working in the centre to perform all the reviews. The 
NeoSCOPE11 trial was re-introducing neoadjuvant chemoradiotherapy prior to 
oesophagectomy into the UK and there were concerns about increasing post-operative 
morbidity and mortality with this approach.  In order to ensure that non protocol-compliant 
RT was not the cause for any excess toxicity, prospective ICR review of all cases up to the 
first toxicity assessment (after 20 patients had completed treatment) was undertaken. This 
necessitated a more sustainable approach to prospective ICR, allowing multiple reviewers 
not necessarily based at one of the RTTQA centres to participate in the process, without 
compromising on quality. Here we report on how we achieved this. 
Methods 
For the purpose of ICR we implemented a specific IT infrastructure and workflow that could 
serve all organisations involved in the RTQA process. The main requirements that we 
identified for the former are outlined in Table 1. The CERR (Computational Environment for 
Radiotherapy Research) met all of these requirements. It was custom built and validated for 
the purpose of analysing and  sharing RT data for research purposes12 and our RTTQA group 
had previous experience of its use .13 A compiled version (a stand alone version without the 
need for license or specific IT infrastructure) was provided by the Database and IT Solutions 
subgroup of the UK RTTQA group2. It can be downloaded at a remote site within minutes 
and a user guide is also made available.  
Results 
The workflow process 
                                                          
1 http://www.ctc.ucl.ac.uk/TrialDetails.aspx?TrialID=48 
2 http://www.rttrialsqa.org.uk/rttqa/ 
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 In step 1 all centres were asked to submit the outlining data (all target volumes including 
organs at risk) in DICOM format along with the relevant diagnostic information (CT, EUS and 
PET reports). The former was done with the centre-specific Treatment Planning System 
(TPS). Data was anonymised at the treating centre, as per trial regulations and  exported in 
DICOM format, and securely transmitted to the RTTQA Centre.. All transferred data was 
stored locally on a dedicated RTTQA drive. 
Centres were encouraged to submit outlining as soon as it was available, and given the 
option to either wait for feedback, or proceed with the planning on the understanding that 
the outlines may need to be modified. In step 2, anonymised DICOM data were received by 
our RTTQA Centre and were checked for integrity and validated by the trial QA contact. This 
consisted of ensuring all data was complete and anonymised and could be processed in 
CERR, along with a visual check of the outlines and correlation with the plan assessment 
form. Data were then processed and packaged in the CERR12 binary format and securely 
transmitted to the expert reviewer at the designated remote organisation. In step 3 the 
expert reviewer received the binary package, which was opened and reviewed using the 
distributed CERR-compiled application. The review was then carried out, a standardised 
report prepared and submitted to our RTTQA Centre and sent to the respective centre. 
Dialogue between the reviewer and the centre was undertaken if an unacceptable deviation 
or a data query was identified.  A detailed review of the planning was also undertaken but is 
beyond the scope of this paper.  
Use of the workflow in NeoSCOPE 
The ICRs for outlining in this trial were undertaken by 5 upper GI clinical oncologists (SG, TC, 
SM, MH, GR, all NeoSCOPE Trial Management Group members) on a rota basis, only one of 
whom was based at the RTTQA centre. Reviews for patients outlined using 3D or 4DCT (both 
allowed in the trial) were assigned according to the expertise of the reviewers. In order to 
minimise inter-reviewer variation, all of the reviewers had been part of the RT protocol 
development group and had undertaken the pre-accrual assessment process in their 
respective centres. A standardised proforma for review and feedback was used, which 
detailed pre–agreed acceptable and unacceptable deviations for outlining.  
Prospective ICR was undertaken for the first 20 patients recruited to the trial as described 
above, regardless of recruiting centre and previous performance. However, as recruitment 
from the 15 participating centres was not at the same rate, prospective ICR was also 
extended to the first recruited case from each centre, repeating the process if there were 
any unacceptable deviations, until there was a satisfactory submission. Centres were 
expected to correct any unacceptable deviations and resubmit outlining for approval, prior 
to commencing treatment. The intention was to feed back to centres within 3 working days 
and this was achieved in 75% of reviews with a median of 2 days.  There were no delays in 
treatment start date. Subsequent cases were subject to ͚tiŵely retrospectiǀe reǀieǁ͛, with 
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review within 2 weeks (10/25#) of the start of RT. This approach was intended to minimise 
the burden of the initial rigorous QA requirements on departments which were performing 
well, but still allow identification of a significant error in sufficient time for correction to be 
made to at least half the number of remaining fractions. This target was achieved in 93% of 
reviews, with 40% before the start of treatment. 39 (47%) real-time and 44 (53%) timely- 
retrospective reviews were undertaken. 9 cases required resubmission, 6(67%) were real 
time and 3(33%) timely retrospective. The compiled version of CERR has now been made 
available to the other  RTTQA centres for trials involving a range of anatomical sites.  
Discussion  
Historically, most RTQA of gastrointestinal RT trials has been retrospective2. Given recent 
evidence for the relationship between protocol deviations and poor outcome, we no longer 
believe it is acceptable to simply collect the data on deviations retrospectively, since there is 
no opportunity to correct prior to, or during the course of the treatment, or to provide 
feedback to the clinician involved. However, the move to prospective ICR is both labour and 
resource intensive14,15. If prospective ICR is to be performed in a timely manner and avoid 
delays iŶ the patieŶt͛s treatŵeŶt, feedback to centres is needed within 3 working days. The  
RTTQA group has limited funding to provide the expertise for outlining review and the four 
centres are not expected to offer high level clinical expertise in outlining, which is viewed to 
be the responsibility of the Chief Investigator or nominated radiotherapy lead. In reality the 
workload and timescales are too onerous for a single clinician in most cases and there has 
been an urgent need to develop a robust process to involve multiple reviewers, who would 
often be based  outside of the four  RTTQA centres  
The first trial to use prospective ICR in our RTTQA centre was ARISTOTLE. In this trial a single 
clinician reviewed all the outlines and provided feedback to centres within 48 hours. While 
feasible for this particular trial as one of the lead members of the Trial Management Group 
was based at the RTTQA centre, this is not a model that can be applied to all trials and a 
move towards a multi-clinician approach is recommended.  We have been able to 
implement a distributed review process through the use of a secure, fast and reliable IT 
infrastructure and a distributed application specifically designed to review RT data. The 
application used in this work is platform independent, enabling the review to be conducted 
under the same conditions as if the review was conducted in the RTTQA centre.   
Recently Skripcak et al.16 reported on challenges and possible solutions for the strategic 
development of international research data exchange framework in radiation therapy and 
oncology and identified three major classes of data pooling models: Centralised, 
Decentralised and Hybrid. Our approach used a decentralised model in which data are 
collected, validated and processed at the designated RTTQA centre by expert trial QA staff. 
These data are then securely transmitted to the review sites, as appropriate, in anonymised 
form. In this model the applications needed to technically access the data and review the 
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clinical case are distributed and installed at the review centre and managed by the local IT 
department, following local rules and security protocols. Furthermore our approach 
minimises possible interoperability issues between the different clinical IT solutions 
implemented in institutions participating to the trial. The procedure that we implemented 
ensures completeness and quality of the data submitted for review to individual centres 
because the information is processed, validated and standardised in a single file format that 
is checked for integrity before leaving the RTTQA centre. This also facilitates and speeds up 
the real time review process.  
Different approaches have been adopted to address the issue of prospective ICR 14,15,17-19. 
The EORTC have reported the development of a digital central review facility, where centres 
upload data through a secure website and then the reviewers, who may not be based at the 
central RTQA centre, are able to remotely access the data through a terminal server20. The 
International Society of Paediatric Oncology (Europe) high risk neuroblastoma group have 
developed a web-based platform which allows remote uploading of radiology and RT-
related data and images from the participating centres, allowing remote review by clinicians 
in a timely fashion, without the need to meet in one place at one time19. In the USA, the 
leading QA centres serving the current National Cancer Institute clinical trial programme 
have been brought together to form a single organisation administered by the American 
College of Radiology Clinical Research Centre in Philadelphia. This new organisation, will be 
known as the Imaging and Radiation Oncology Core Group18. Real-time reviews are 
conducted by a faculty from the University of Massachusetts. Study chairs wishing to 
perform retrospective reviews have a secure Virtual Private Network (VPN) connection to 
the database and can access the information (T Fitzgerald, personal communication). 
SWAN17 was developed in Australia with the aim of facilitating objective analysis, quality 
assurance and review of digital treatment planning data from TROG multi-centre RT trials. It 
is utilised for central review, pre-accrual benchmark cases and credentialing. It has unique 
properties in that it can perform automatic reviews and reporting which allows specific 
fields in a data export to be examined for adherence to protocol criteria. While not 
removing the need for manual review, it can reduce the time needed for review by 
identifying errors in data submission prior to being sent to a clinician for review.  
The trend is for trials to become more complex and more costly14. Continued progress 
requires dedicated resources. Plan reviews and dosimetry audits have been supported by 
funding of dedicated physicist time, but across Europe most of the outlining reviews are 
undertaken by clinicians (e.g. chief investigators or other member of the trial management 
group) on a voluntary basis,, or by clinical fellows supported by grants from various 
sources14. The RTOG have shown that in four of their trials, including the most recent trial of 
IMRT for anal cancer, the major deviations were inaccurate target volume  delineation3 and 
additional resources are needed to ensure we can continue to provide high quality review of 
outlining for future trials. 
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Conclusion 
Our distributed RTQA review approach provides a method of prospective outlining review at 
multiple centres, without compromising quality, delaying start of treatment or need for 
significant additional resources.  Future progress in the area of prospective ICR will need to 
be supported by additional resources for clinician time to undertake the reviews. 
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Table 1 – Summary of main requirements for the UK RTTQA workflow and software to be 
used for real time review of multi-centre radiotherapy trials. 
Workflow Comply with good clinical practice and data protection regulations 
Decentralised or hybrid data pooling model 
Accessible and secure data transfer 
Network speed and reliability 
Validation of completeness and quality of data 
Standardisation of data format and consistent quality review moving from a 
single to a multiple site basis 
Simplified process that meets prospective ICR requirements  
Software Distributable to both RTTQA and non-RTTQA centres 
Operating system independent 
Standalone with no additional equipment required  
Read in digital data exported from multiple TPS and PACS (DICOM, DICOM-RT, 
RTOG formats) 
Easy to use with functionalities and tools similar to those found in TPS 
Centrally developed and maintained 
Locally managed (IT remote organisation) 
 
TPS – treatment planning system, ICR – individual case review, PACS – picture archiving and 
information system, RT – radiotherapy 
 
Table
